research FCE 28260, A New 5α-Reductase Inhibitor: In Vitro and In Vivo Effects
FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.
Search
for
Sort by
Research
30 / 1000+ results 
research Finasteride: The First 5α-Reductase Inhibitor
Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
research Is Dihydrotestosterone a Classic Hormone?
Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.
research Effect of MK-386, a Novel Inhibitor of Type 1 5 Alpha-Reductase, Alone and in Combination with Finasteride, on Serum Dihydrotestosterone Concentrations in Men
MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
research 5α-Reductase Inhibitors
Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
research A New Look at the 5-Alpha-Reductase Inhibitor Finasteride
Finasteride treats enlarged prostate and hair loss, but may cause side effects in some patients.
research 5α-Reductase Inhibitors in the Treatment of Androgenetic Alopecia
Finasteride improves hair growth in men with androgenetic alopecia.
research Is Dehydroepiandrosterone a Hormone?
Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.
research Administration of Caesalpinia Bonduc Seed Extracts Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia in Male Wistar Rats
Caesalpinia bonduc seed extracts may help treat enlarged prostate in rats.
research Inhibitors of 5α-Reductase in the Treatment of Benign Prostatic Hyperplasia
5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride
Dutasteride more effective for hair growth, but has more side effects than finasteride.
research Inhibitory Effects of Pueraria Mirifica Aqueous Extracts on 5α-Reductase and Prostate Histomorphometry in Testosterone-Induced Benign Prostatic Hyperplasia Sprague Dawley Rats
Pueraria mirifica extract may help treat benign prostatic hyperplasia.
research Alpha-Spinasterol from Melandrium Firmum Attenuates Benign Prostatic Hyperplasia in a Rat Model
α-spinasterol from Melandrium firmum can help reduce prostate enlargement.
research Benign Prostatic Hyperplasia: A Disorder of Androgen Metabolism in Males
Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.
research PNU 157706, A Novel Dual Type I and II 5α-Reductase Inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research The Dihydrotestosterone Hypothesis of Prostate Cancer and Its Therapeutic Implications
The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
research A Novel Finasteride 0.25% Topical Solution for Androgenetic Alopecia: Pharmacokinetics and Effects on Plasma Androgen Levels in Healthy Male Volunteers
New finasteride solution effectively reduces baldness-causing hormone, potentially with fewer side effects.
research The Rationale for Inhibiting 5α-Reductase Isoenzymes in the Prevention and Treatment of Prostate Cancer
Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.
research A Model for the Turnover of Dihydrotestosterone in the Presence of the Irreversible 5α-Reductase Inhibitors GI198745 and Finasteride
Both drugs lower DHT levels, with GI198745 being more effective.
research Influence of Dosing Time on the Efficacy and Safety of Finasteride in Rats
Dosing time affects finasteride's effectiveness and safety in rats.
research Serum Concentrations of Dihydrotestosterone Are Associated With Symptoms of Hypogonadism in Biochemically Eugonadal Men
Higher DHT levels are linked to fewer hypogonadism symptoms in men with normal testosterone levels.
research Steady-State Pharmacokinetics of Oral Testosterone Undecanoate with Concomitant Inhibition of 5α-Reductase by Finasteride
Finasteride doesn't affect oral testosterone undecanoate, and high DHT levels may cause acne, prostate issues, and hair loss.
research Clinical Pharmacokinetics and Pharmacodynamics of Finasteride
Finasteride helps regrow hair and shrink prostate by reducing DHT, with some sexual side effects.
research Combination of an Antiandrogen and a 5α-Reductase Inhibitor: A Further Step Towards Total Androgen Blockade?
Using two drugs together, Flutamide and 4-MA, is more effective for blocking male hormones than using each one alone.
research Pre-Receptor Regulation of the Androgen Receptor
Two enzymes regulate androgen receptor activity, affecting treatments for androgen insufficiency and benign prostatic hyperplasia.
research Recent Advances in Drug Design and Drug Discovery for Androgen-Dependent Diseases
New treatments for prostate cancer and BPH show promise, including novel compounds that target hormone synthesis and response.
research Why Are Men With Premature Alopecia at Higher Risk of Benign Prostatic Hyperplasia? And What About Prostate Cancer?
Men with early hair loss may have a higher risk of enlarged prostate and possibly prostate cancer due to shared hormonal factors.
research Dutasteride: A Review of Its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research Clinical Use of 5α-Reductase Inhibitors
Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.